spacer
home > ebr > winter 2009 > quality control
PUBLICATIONS
European Biopharmaceutical Review

Quality Control

Quality control is too often perceived simply as the last phase in the many stages of product manufacture; a box ticking exercise to check that what has been made meets the required specification. However, quality control should be considered as a key driver for increasing product value. In a multiproduct biopharmaceutical facility that manufactures products using a wide range of technology platforms, efficient, effective and appropriate quality control is fundamental to business success.

Effective quality control begins well before a product or project even enters the manufacturing facility; ensuring the quality of the manufacturing environment, utilities and cleaning are key to determining project success or failure. The main aim of many quality groups has often been to develop the necessary systems to obtain a license for a facility or product...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kate Westwell is a QC Microbiologist at Eden Biodesign with eight years’ experience in microbiological techniques and industry practices. She previously lead a Microbiology Department in a large pharmaceutical company ensuring strict regulatory and cGMP compliance (Chiron). Experienced in environmental monitoring, product and utilities testing, assay and equipment validation, as well as provision of technical support and microbiological guidance.

Gina Wenham is an Analytical Development Manager at Eden Biodesign Ltd. She is an experienced technical manager with 19 years’ pharmaceutical experience. She has held key positions in the pharmaceutical industry as a technical manager of both development and quality control groups (ML Laboratories), managed the development and validation of QC tests and procedures for a range of the companies products from clinical trials materials through to licensed products. She has also successfully prepared laboratories for MHRA, FDA and BSI accreditation.

spacer
Kate Westwell
spacer
spacer
spacer
Gina Wenham
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Samsung Biologics Reports Third Quarter 2022 Financial Results

Recorded consolidated revenue of KRW 873 billion in Q3’22, and recorded consolidated operating profit of KRW 324.7 billion in Q3’22. Also started partial operations at Plant 4 within 23 months since groundbreaking as previously committed and launched two
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement